Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/03/18 21:10:57」(JST)

wiki en

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008^[1] and by the European Medicines Agency (EMA) on January 11 of the same year.^[2]

References

^ "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Retrieved 2008-03-15.
^ "European Public Assessment Report for Ivemend (from the EMEA website)". Retrieved 2008-03-15.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 緩和ケアの最新情報 whats new in palliative care
2. 化学療法誘発性悪心および嘔吐の予防および治療 prevention and treatment of chemotherapy induced nausea and vomiting
3. 制吐剤の特性 characteristics of antiemetic drugs
4. 化学療法誘発性悪心および嘔吐の病態生理および予測 pathophysiology and prediction of chemotherapy induced nausea and vomiting
5. 麻酔後ケア病棟における合併症発生の概要 overview of complications occurring in the post anesthesia care unit

English Journal

Japanese Journal

新規NK1 receptor antagonist(fosaprepitant)ホスアプレピタントについて

福正りさ,松本光史
腫瘍内科 10(2), 145-161, 2012-08-00
NAID 40019416704

海外の新薬審査情報を読み解く(第3回)ホスアプレピタント(Fosaprepitant)

野村香織
月刊薬事 54(3), 469-471, 2012-03-00
NAID 40019218413

Related Pictures

Fosaprepitant ( Ivemend®) Fosaprepitant-Dimeglumin |Ivemend ® |14 Fosaprepitant (free base) fosaprepitant fosaprepitant emend for Description Fosaprepitant.svg Buy Fosaprepitant dimeglumine salt | Price Drugs reference index « fosaprepitant » Fosaprepitant dimeglumine CAS 265121-04-8

★リンクテーブル★

リンク元	「ホスアプレピタント」
拡張検索	「fosaprepitant dimeglumine」

「ホスアプレピタント」

Fosaprepitant
Clinical data
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a604003
License data	EU EMA: Ivemend; US FDA: Fosaprepitant;
Pregnancy; category	US: B (No risk in non-human studies); ;
Routes of; administration	Intravenous
ATC code	A04AD12 (WHO);
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>95% (aprepitant)
Metabolism	To aprepitant
Biological half-life	9 to 13 hours (aprepitant)
Identifiers
	IUPAC name [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid;
CAS Number	172673-20-0 ;
PubChem CID	219090;
IUPHAR/BPS	7623;
DrugBank	DB06717 ;
ChemSpider	189912 ;
UNII	6L8OF9XRDC;
KEGG	D06597 ;
ChEBI	CHEBI:64321 ;
ChEMBL	CHEMBL1199324 ;
Chemical and physical data
Formula	C23H22F7N4O6P
Molar mass	614.406 g/mol
3D model (Jmol)	Interactive image;
	SMILES C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)Cc3[nH]c(=O)n(n3)P(=O)(O)O)c4ccc(cc4)F ;
	InChI InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1 ; Key:BARDROPHSZEBKC-OITMNORJSA-N ;
(what is this?) (verify)

　　[★]

英: fosaprepitant
化: ホスアプレピタントメグルミン fosaprepitant dimeglumine
商: プロイメンド
関: 鎮吐薬。その他の消化器官用薬

選択的ニューロキニン１（ＮＫ１）受容体拮抗型制吐剤

「fosaprepitant dimeglumine」

　　[★]

フォサプレピタント・ジメグルミン

[1] "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Retrieved 2008-03-15.

[2] "European Public Assessment Report for Ivemend (from the EMEA website)". Retrieved 2008-03-15.

v t e Antiemetics (A04)

5-HT₃ serotonin ion channel antagonists	Alosetron Azasetron Bemesetron Cilansetron Clozapine Dazopride Dolasetron Granisetron Lerisetron Metoclopramide Mianserin Mirtazapine Olanzapine Ondansetron Palonosetron (+netupitant) Quetiapine Ramosetron Ricasetron Tropisetron Zatosetron

5-HT serotonin G-protein receptor antagonists	Clozapine Cyproheptadine Hydroxyzine Olanzapine Risperidone Ziprasidone

CB₁ agonists (cannabinoids)	Dronabinol Nabilone Tetrahydrocannabinol (cannabis)

D₂/D₃ antagonists	Alizapride Bromopride Chlorpromazine Clebopride Domperidone Haloperidol Hydroxyzine Itopride Metoclopramide Metopimazine Prochlorperazine Thiethylperazine Trimethobenzamide

H₁ antagonists (antihistamines)	Cyclizine Dimenhydrinate Diphenhydramine Hydroxyzine Meclizine Promethazine

mACh antagonists (anticholinergics)	Atropine Diphenhydramine Hydroxyzine (very mild) Hyoscyamine Scopolamine

NK₁ antagonists	Aprepitant Casopitant Ezlopitant Fosaprepitant Maropitant Netupitant Rolapitant Vestipitant

Others	Cerium oxalate Dexamethasone Lorazepam Midazolam Propofol

v t e Anxiolytics (N05B)

5-HT_1A agonists	Buspirone Tandospirone

GABA_AR PAMs	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam Others: Alpidem^‡ Barbiturates Carbamates Chlormezanone^‡ Ethanol Etifoxine; Herbs: Kava Skullcap Valerian

α₂δ VDCC blockers	Gabapentin Gabapentin enacarbil Phenibut Pregabalin

Antidepressants	SSRIs SNRIs SARIs TCAs TeCAs MAOIs; Others: Agomelatine Bupropion Vilazodone Vortioxetine

Sympatholytics	Beta blockers (e.g., propranolol) Clonidine Dexmedetomidine Guanfacine Prazosin

Others	Benzoctamine Cannabidiol Cycloserine Fabomotizole Hydroxyzine Kanna Lavender Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum

匿名

検索

案内

案内

fosaprepitant